IL-7 as a potential therapy for HIV-1-infected individuals

Bibliography

• POMERANTZ RJ: Residual HIV-1 replication. Biomed. Pharmacother. (2000) 54:13–16.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RJ: HIV-1 residual replication anti-retroviral therapy. J. Internad AIDS Care (2000) 2:1–12.
   Google Scholar
• POMERANTZ RJ, ZHANG H: Residual HIV-1 persistence during suppressive HAART. In: Current Clinical Topics in Infectious Diseases. Remington J, Swartz M (Eds), Blackwell Science, Inc., Malden, MA, USA (2001):1–30.
   Google Scholar
• POMERANTZ RJ: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Biomed. Pharmacother. (2001) 55:7–15.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RJ: The sanctuaries of HIV-1. Updates AIDS (2001) 1:1–12.
   Google Scholar
• POMERANTZ RJ: HIV-1 reservoirs: the major obstacle to viral eradication. Clin. Infect. Dis. (2002) 34:91–97.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RJ: Eliminating HIV-1 reservoirs. Curr. Opin. Investig. Drugs (2002) 3(8):1133–1137.
   PubMedGoogle Scholar
• POMERANTZ RJ: HIV-1 reservoirs. In: HIV and AIDS, Clinics in Laboratory Medicine. W.B. Saunders, Inc., Philadelphia, PA, USA (2002):573–593.
   Google Scholar
• POMERANTZ RJ: HIV-1 reservoirs. In: Current Topics in HIT/-I Medicine. Mayer KH (Ed.), The Infectious Diseases Society of America, USA (2002):35–42.
   Google Scholar
• POMERANTZ RJ: Reservoirs, sanctuaries and residual disease: the hiding spots of HIV-1. HIV Chn. Trials (2003) 4(2):1–8.
   PubMedGoogle Scholar
• KULKOSKY J, POMERANTZ RJ: Approaching eradication of HAART persistent HIV-1 reservoirs with immune activation therapy (TAT). Clin. Infect. Dis. (2002) 35:1520–1526.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RJ, LAFEUILLADE A: HIV-1 persistence during therapy. HIV Chn. Trials (2004) 5:1–7.
   PubMedGoogle Scholar
• POMERANTZ RJ: Residual HIV-1 infection during anti-retroviral therapy: the challenge of viral persistence. AIDS (2001) 15:1201–1211.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RJ: HIV-1 cross-talk andviral reservoirs. Nature (2003) 424:136–137.
   PubMed Web of Science ®Google Scholar
• ZHANG H, DORNADULA G, BEUMONT M et al.: HIV-1 in the semen of men receiving highly active anti-retroviral therapy (HAART). N Engl J. Med. (1998) 339:1803–1809.
   PubMed Web of Science ®Google Scholar
• DORNADULA GH, ZHANG B, VANUITERT Jet al.: Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART). JAMA (1999) 282:1627–1632.
   Google Scholar
• DORNADULA G, NUNNARI G, VANELLA M et al.: HIV-1-infected individuals with residual disease on suppressive HAART can be stratified into relevant virological and immunological subgroups. J. Infect. Dis. (2001) 183:1682–1687.
   PubMedGoogle Scholar
• KULKOSKY J, NUNNARI G, OTERO M et al.: Intensification and stimulatory therapy for HIV-1 reservoirs in infected individuals on virally-suppressive HAART. J. Infect. Dis. (2002) 186:1403–1411.
   PubMedGoogle Scholar
• KULKOSKY J, CULNAN DM, ROMAN J et al.: Prostratin: Inhibition of HIV-1 infection and induction of latent viral expression suggests a potential adjuvant therapy for HAART. Blood (2001) 98:3006–3015.
   PubMed Web of Science ®Google Scholar
• KULKOSKY J, SULLIVAN J, XU Y, SOUDER E, HAMER DH, POMERANTZ RJ: Expression of latent, HAART-persistent HIV-1 induced by novel cellular activating agents. AIDS Res. Hum. Retroviruses (2004) 20:497–505.
   PubMed Web of Science ®Google Scholar
• WANG F-X, XU Y, SULLIVAN J et ell.: IL-7 is a potent and proviral strain-specific inducer of latent, in vivo HIV-1 cellular reservoirs of infected individuals on virally-suppressive HAART. j Clin. Invest. (2005) 115:128–137.
   Google Scholar
• DIMASCIO M, DORNADULA G, ZHANG H et al.: In a subset of subjects on highly active antiretroviral therapy plasma HIV-1 plasma HIV-1 RNA decays from 50 copies/ml to 5 copies/ml with a half-life of six months. J. Wrol. (2003) 77:2271–2275.
   Google Scholar
• NUNNARI G, OTERO M, DORNADULA G et al.: Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS (2002) 16:39–45.
   PubMed Web of Science ®Google Scholar
• OTERO M, NUNNARI G, LETO D et al.:Peripheral blood dendritic cells are not a major reservoir for HIV-1 in infected individuals on virally-suppressive HAART. AIDS Res. Hum. Retroviruses (2003) 19:1097–1103.
   PubMed Web of Science ®Google Scholar
• KULKOSKY J, SULLIVAN J, XU Yet al.:Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo. Virology (2003) 314:617–629.
   Google Scholar
• POMERANTZ RJ, LAFEUILLADE A: HIV-1 persistence during therapy. HIV Chn. Trials (2004) 5:1–7.
   PubMedGoogle Scholar
• DESIMONE JA, POMERANTZ RJ: Prospects for treating HAART-persistent reservoirs in individuals with HIV-1 infection. MD Consult. - Infect. Dis. (2003) 10(141–7.
   Google Scholar
• SILICIANO JD, KAJDAS J, FINZI D et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. (2003) 9:727–728.
   PubMed Web of Science ®Google Scholar
• EMERY S, CAPRA WB, COOPER DA et al.: Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy inadult human immunodeficiency virus Type 1 disease. 1 Infect. Dis. (2000) 182:428–434.
   Google Scholar
• PANDOLFI F, PIERDOMINICI M, MARZIALI M et al.: Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin. Immunol (2000) 94:153–159.
   PubMed Web of Science ®Google Scholar
• PETT SL, EMERY S: Immunomodulatorsas adjunctive therapy for HIV-1 infection. 1 Clin. Wrol. (2001) 22:289–295.
   Google Scholar
• TAMBUSSI G, GHEZZI S, NOZZA S et al.: Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. J. Infect. Dis. (2001) 183:1476–1484.
   PubMed Web of Science ®Google Scholar
• CHUN TW, ENGEL D, MIZELL SB et al.: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. (1999) 5:651–655.
   PubMed Web of Science ®Google Scholar
• STELLBRINK HJ, VAN LUNZEN J, WESTBY M et al.: Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS (2002) 26:1479–1487.
   Google Scholar
• NAMEN AE, SCHMIERER AE, MARCH CJ et al.: B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J. Exp. Med. (1998) 167:988–1002.
   Google Scholar
• BENJAMIN D, SHARMA V, KNOBLOCH TJ, ARMITAGE RJ, DAYTON MA, GOODWIN RG: Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J. Immunol. (1994) 152:4749–4757.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ E, VICENTE A, ZAPATA A et al.: Establishment and characterization of cloned human thymic epithelial cell lines. Analysis of adhesion molecule expression and cytokine production. Blood (1994) 83:3245–3254.
   Google Scholar
• WATANABE M, UENO Y, YAJIMA T et al.: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. (1995) 95:2945–2953.
   PubMed Web of Science ®Google Scholar
• RYAN DH, NUCCIE BL, RITTERMAN I, LIESVELD JL, ABBOUD CN: Cytokine regulation of early human lymphopoiesis. j Immunol. (1994) 152:5250–5258.
   PubMed Web of Science ®Google Scholar
• KRONCKE R, LOPPNOW H, FLAD HD, GERDES J: Human follicular dendritic cells and vascular cells produce interleukin-7: a potential role for interleukin-7 in the germinal center reaction. Eur. j Immunol (1996) 26:2541–2544.
   PubMed Web of Science ®Google Scholar
• VELLA AT, DOW S, POTTER TA, KAPPLER J, MARRACK P: Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl Acad. Sci. USA (1998) 95:3810–3815.
   PubMed Web of Science ®Google Scholar
• VELLA A, TEAGUE TK, IHLE J, KAPPLER J, MARRACK P: Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: STAT6 is probably not required for the effect of IL-4.1 Exp. Med. (1997) 186:325–330.
   PubMed Web of Science ®Google Scholar
• BOISE LH, MINN AJ, JUNE CH, LINDSTEN T, THOMPSON CB: Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc. Natl Acad. Sci. USA (1995) 92:5491–5495.
   PubMed Web of Science ®Google Scholar
• KOMSCHLIES KI,, GREGORIO TA, GRUYS ME, BACK TC, FALTYNEK CR, WILTROUT RH: Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J. Immunol (1994) 152:5776–5784.
   PubMed Web of Science ®Google Scholar
• GRZEGORZEWSKI KJ, KOMSCHLIES KI,, JACOBSEN SE, RUSCETTI FW, KELLER JR, WILTROUT RH: Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin 7.1 Exp. Med. (1995) 181:369–374.
   Google Scholar
• CARINI C, ESSEX M: Interleukin 2-independent interleukin 7 activity enhances cytotoxic immune response of HIV-1-infected individuals. AIDS Res. Hum. Retroviruses (1994) 10:121–130.
   PubMed Web of Science ®Google Scholar
• BUI T, DYKERS T, HU SL, FALTYNEK CR, HO RJ: Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. J. Acquir. Immune Defic. Syndr. (1994) 7:799–806.
   PubMed Web of Science ®Google Scholar
• KAECH SM, TAN JT, WHERRY EJ, KONIECZNY BT, SURH CD, AHMED R: Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol (2003) 12:1191–1198.
   Google Scholar
• GOODWIN RG, FRIEND DJ, ZIEGLER SF et al.: Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell (1990) 60:941–951.
   PubMed Web of Science ®Google Scholar
• LEONARD WJ: Cytokines and immunodeficiency disease. Nat. Rev. Immunol. (2001) 1:200–208.
   PubMed Web of Science ®Google Scholar
• LAI SY, MOLDEN J, GOLDSMITH MA: Shared ye subunit within the human interleukin-7 receptor complex. Clin. Invest. (1997) 99(2):169–177.
   Google Scholar
• LIN JX, MIGONE TS, TSANG M et al.: The role of shared receptor motifs and common stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity (1995) 2:331–339.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI T, KAWAHARA A. FUJII H et al.: Functional activation ofJakl and Jak3 by selective association with IL-2 receptor subunits. Science (Wash. DC) (1994) 266:1045–1047.
   Google Scholar
• COSENZA L, GORGUN G. URBANO A, FOSS F: Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell. Signal. (2002) 14:317–325.
   PubMed Web of Science ®Google Scholar
• WILKS AF, HARPUR AG: Cytokine signaltransduction and the JAK family of protein tyrosine kinase. Bioessays (1994) 16:313–320.
   PubMed Web of Science ®Google Scholar
• CROSS TG, SCHEEL-TOELLNER D, HENRIQUEZ NV, DEACON E, SALMON M, LORD JM: Serine/threonine protein kinases and apoptosis. Exp. Cell Res. (2000) 256:34–41.
   PubMed Web of Science ®Google Scholar
• DUDLEY AC, THOMAS D, BEST J, JENKINS k The STATs in cell stress-type responses. Cell Commun. Signal. (2004) 2(8):1478–1481.
   Google Scholar
• JALECO S, SWAINSON L, DARDALHON V, BURJANADZE M, KINET S, TAYLOR N: Homeostasis of naïve and memory CD4+ T-cell: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J. Immunol (2003) 171:61–68.
   PubMed Web of Science ®Google Scholar
• NAPOLITANO LA, GRANT RM, DEEKS SG et al.: Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. (2001) 7:73–79.
   PubMed Web of Science ®Google Scholar
• LLANO A, BARRETINA J, GUTIERREZ A et al.: Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus Type 1-positive individuals. J. ViroL (2001) 21:10319–10325.
   Google Scholar
• SMITHGALL MD, WONG JG, CRITCHETT KE, HAFFAR OK: IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. J. ImmunoL (1996) 156:2324–2330.
   PubMed Web of Science ®Google Scholar
• CHENE L, NUGEYRE MT, GUILLEMARD E, MOULIAN N, BARRE-SINOUSSI F, ISRAEL N: Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(-) CD3(+) thymocytes: a critical role for tumor necrosis factor and interleukin-7. J. ViroL (1999) 73:7533–7542.
   PubMed Web of Science ®Google Scholar
• MORAN PA, DIEGEL ML, SIAS JC, LEDBETTER JA, ZARLING JM: Regulation of HIV production by blood mononuclear cells from HIV-infected donors: I. Lack of correlation between HIV-1 production and T cell activation. AIDS Res. Hum. Retroviruses (1993) 9:455–464.
   PubMed Web of Science ®Google Scholar
• SCRIPTURE-ADAMS DD, BROOKS DG, KORIN YD, ZACK JA: Interleukin-7 induces expression of latent human immunodeficiency virus Type 1 with minimal effects on T-cell phenotype. J. ViroL (2002) 76:13077–13082.
   PubMed Web of Science ®Google Scholar
• SOARES MV BORTHWICK NJ, MAINI MK, JANOSSY G, SALMON M, AKBAR AN: IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. ImmunoL (1998) 161:5909–5917.
   Web of Science ®Google Scholar
• UNUTMAZ D, KEWALRAMANI VN, MARMON S, LITTMAN DR: Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes./ Exp. Med. (1999) 189:1735–1746.
   PubMed Web of Science ®Google Scholar
• CHUN T-W, ENGEL D, MIZELL SB et al.: Effect of interleukin-2 on the pool of latently infected resting CD4+ cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat. Med. (1999) 5:651–655.
   PubMed Web of Science ®Google Scholar
• PRINS JM, JURRIAANS S, VAN PRAAG RM et al.: Immunoactivation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 13:2405–2410.
   Google Scholar
• FRASER C, FERGUSON NM, GHANI AC et al.: Reduction of the HIV-1 infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS (2000) 14:659–669.
   PubMed Web of Science ®Google Scholar
• LAFEUILLADE A, POGGI C, CHADAPAUD S et al.: Pilot study of a combination of highly active anti-retroviral therapy and cytokines to induce HIV-1 remission. J. AIDS (2001) 26:44–55.
   PubMed Web of Science ®Google Scholar
• CHUN T-W, ENGEL D, MIZELL SB et al.: Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. (1998) 188:83–91.
   PubMed Web of Science ®Google Scholar
• ELLENHORN JD, WOODLE ES, GHOBREAL I et al.: Activation of human T cells in vivo following treatment of transplantation recipients with OKT3. Transplantation (1990) 50:608–612.
   PubMed Web of Science ®Google Scholar
• VAN PRAAG RM, PRINS JM, ROOS MT et al.: OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. ImmunoL (2001) 21:218–226.
   PubMed Web of Science ®Google Scholar
• NUGEYRE MT, MONCEAUX V, BEQ S et al.: L-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. ImmunoL (2003) 171:4447–4453.
   Web of Science ®Google Scholar
• FRY TJ, MONIUSZKO M, CREEKMORE S et aL: IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood (2003) 101:2294–2299.
   PubMed Web of Science ®Google Scholar
• BROOKS DG, HAMER DH, ARLEN PA: Molecular characterization, reactivation and depletion of latent HIV. Immunity (2003) 19:413–423.
   PubMed Web of Science ®Google Scholar